Investigators examined and summarized the evidence from 13 randomized trials involving more than 2,000 patients. They found:
1. Patients with community-acquired pneumonia who received corticosteroids were discharged from the hospital one day sooner than patients who did not receive corticosteroid therapy.
2. Corticosteroid treatment reduced the need for mechanical ventilation (or the requirement for a breathing tube) from 9 percent to 5 percent of patients and the likelihood of developing acute respiratory distress syndrome from 8 percent to 2 percent of patients.
3. The steroid treatment was also linked to a significant reduction in death rates from 9 to 10 percent of patients down to 5 to 6 percent.
“Our study should lead to an important change in treatment for pneumonia,” said lead author Dr. Reed Siemieniuk, MD, a physician and a graduate student at McMaster University. “Corticosteroids are inexpensive and readily available around the world. Millions of patients will benefit from this new evidence.”
More articles on pneumonia:
AHRQ: Inpatient death rates down for 4 high-volume conditions
Research links liver to pneumonia, sepsis susceptibility
62% of pneumonia patients have no discernible pathogen, CDC study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
